Navigation Links
The Female Health Company Schedules Second Quarter Conference Call for May 14, 2008
Date:5/7/2008

Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.

For more information about the Female Health Company, visit the Company's web
site at http://www.femalehealth.com and http://www.femalecondom.org.

If you would like to be added to an e-mail alert list, please send an

e-mail to FHCInvestor@femalehealthcompany.com.

Contacts: William R. Gargiulo, Jr. 231-526-1244

Donna Felch, CFO 312-595-9123


'/>"/>
SOURCE The Female Health Company
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. US Female Sterilization Market to Grow to Almost $245 Million Over the Next Five Years
2. Female vets face twice the fertility risk
3. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
4. The Female Health Company Receives USAID DELIVER PROJECT Order for 6.1 Million Units
5. Correction: Therapist to Young Hollywood Says Male Stars in Psychological Trouble Get a Media Pass as Compared to Female Stars
6. Photo: Beverly Hills Liposculpture Specializes in Scarless Breast Reduction Dr. Alan Bittner Reduces Female Breasts by up to 50%
7. The Female Health Company to Present at Growth and Value Investor Conference in Ft. Lauderdale
8. The Female Health Company Reports 37% Revenue Growth and Record Profits for First Quarter of FY2008
9. The Female Health Company Schedules First Quarter Conference Call for February 13, 2008
10. The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application
11. Psychotherapist to Young Hollywood Says Male Stars in Psychological Trouble Get a Media Pass as Compared to Female Stars
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...ntry reported a new suspected case of the disease ... happened hours after doctors gave the cleared a w...n Hyderabed a 48-year-old software worker was imme... from Australia via Singapore. He had symptoms of ...
...ished in the Proceedings for the 2003 Annual Meeti..., suggests that assessing leptin levels may be a m...ring body mass index and the amount of fat in a wo...east cancer are perfect, says lead author Dr Richa...
...researchers from Harvard Medical School has shown ...un over twice the risk of a stroke caused by bleed...fied a link between ischemic stroke - caused by a ...oking. The new study that covered 22,022 male US p...
...for a long time now a lot of health experts that t...ter. It has been advised we shoulddrink at least e... we areadequately hydrated. Researchers from Cente...of Nebraska have now reported that drinking other ...
Other Medicine News:
(Date:10/8/2008)...ical Incorporated (Nasdaq: VICL ),today is presen...ta,demonstrating that the company,s Vaxfectin(R) a...ein-based infectious disease vaccines and,peptide-... Ph.D., Vical,s,Senior Vice President of Product D..., October 8, at the World Vaccine Congress (Lyon, ...
(Date:10/7/2008)... for detecting polyps that can be ...ct. 7 /- At the American College of,G...do (ACG 2008), renowned,gastroenterologist Douglas...tional clinical study that evaluated the efficacy ...at is designed to improve the ability,of physician...
(Date:10/7/2008)...d Immunologic Changes Induced by G...Data Indicates Potential in Treating Inflammatory ... -- Alba Therapeutics Corporation,presented result...can,College of Gastroenterology (ACG) 2008 Annual ... the first Phase IIa trial conducted in celiac dis...
(Date:10/7/2008)...ual Scientific Meeting -, ORLANDO, Fla., Oct. 7 /... Inc. (formerly Microbia, Inc.) and Forest Laborat...entation of results from a Phase,2b study assessin...s with,irritable bowel syndrome with constipation ... daily oral dosing of linaclotide, across a range ...
Breaking Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 1MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 2MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 3MedeFile To Be Marketed in Over 100 000 Retail Outlets 22484 4Boston Scientific Welcomes Progress on Pain Care Legislation 22480 1Boston Scientific Welcomes Progress on Pain Care Legislation 22480 2Boston Scientific Welcomes Progress on Pain Care Legislation 22480 3Boston Scientific Welcomes Progress on Pain Care Legislation 22480 4Medicsight to Present at Piper Jaffray Annual Europe Conference 6145 1Medicsight to Present at Piper Jaffray Annual Europe Conference 6145 2FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 1FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 2FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 3FDA Lifts Clinical Hold on Gentas Tesetaxel a Leading Oral Taxane 2493 4
...e 29, 2007-Preliminary results from,the immunother...ancer Center show a very good safety profile for S...evelopment have been observed,among several patien...with the monoclonal antibody against neuroblastoma...mpany,s report for,the 1st quarter 2007, all 24 pa...
...cacy trends from ongoing phase I/II trial,of oncol...n in,press conference , MARTINSRIED, Germany, June...furt, Prime Standard: MDG) announces that a case,r...s cancer killing,virus will be presented in a pres...cal Oncology. Out of more than 300 posters accepte...
Other Medicine Technology:Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 2Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study 3European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference 2
Introducing the Guidant HEARTSTRING Proximal Seal System. A surgically intuitive system that meets the challenge of clampless hemostasis with a design that is elegant in its simplicity and profound i
...ystem, developed by Given Imaging of Israel, is a ...ape. Weighing in at only four grams, it contains a...ry and radio transmitter coated by a smooth biocom...ymes. Internal gastric images are transmitted to a...
CO2 TMR technology is an effective angina relief therapy for diffuse vessels with poor targets. Because it is easily moved between surgical suites, the CO2 Heart Laser 2 enables the surgeon to make t
TSH EIA Thyroid Function 025-BC-1001
Medicine Products: